(Q77059564)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

title

Epirubicin/vinorelbine as first line therapy in metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

main subject

metastatic breast cancer

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

E Baldini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

C Tibaldi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

F Chiavacci

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

M Di Lieto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

L Fioretto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

A Giallom-bardo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

R Taviani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

P Ghezzi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

A Bolognini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

2 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

129-134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696395%20AND%20SRC:MED&resulttype=core&format=json

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

The Current and Future Place of Vinorelbine in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Phase I pharmacologic study of a new Vinca alkaloid: navelbine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021

Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006059211817

7 January 2021